Results 221 to 230 of about 36,003 (284)
Epilepsia, Volume 67, Issue 4, Page 1679-1689, April 2026.Abstract Objective Antiseizure medications are approved based on clinical trials that demonstrate their efficacy as measured by reductions in seizure frequency (SF). When designing these trials, trialists must select inclusion criteria where SF can be reliably measured to maintain statistical power.
Wesley T. Kerr +6 more
wiley +1 more source
Epilepsia, Volume 67, Issue 4, Page 1690-1702, April 2026.Abstract Objective Topiramate has been linked to increased glaucoma risk, potentially through mechanisms involving ocular fluid shifts. However, comparative risks vs other antiseizure medications (ASMs) and variation by sex or indication remain uncertain.
Cuiling Wei +10 more
wiley +1 more source
Analysis of ASMs and male infertility using the FDA adverse event reporting system (FAERS). [PDF]
Front Public HealthAn K +6 more
europepmc +1 more source
Epilepsia Open, Volume 11, Issue 2, Page 619-626, April 2026.Abstract The SCN1A gene is implicated in a broad spectrum of epilepsy phenotypes, ranging from self‐limited genetic epilepsy with febrile seizures plus (GEFS+) to severe developmental and epileptic encephalopathies such as Dravet syndrome (DS). While fenfluramine (FFA) has demonstrated strong efficacy in DS, its role in SCN1A‐related epilepsies beyond ...
Giovanni B. Dell'Isola +12 more
wiley +1 more source
Pharmacotherapy for Alcohol Craving Reduction: Efficacy of Short-Term Treatments in Alcohol Use Disorder. [PDF]
Medicines (Basel)Cheibub David Marin M +3 more
europepmc +1 more source
Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open‐label prospective study
Epilepsia Open, Volume 11, Issue 2, Page 466-474, April 2026.Abstract Objective CDKL5 deficiency disorder (CDD) is an early‐onset developmental and epileptic encephalopathy characterized by frequent drug‐resistant seizures, cerebral visual impairment, motor dysfunction, and sleep and gastrointestinal disturbances.
Marco Perulli +12 more
wiley +1 more source
Epilepsia Open, Volume 11, Issue 2, Page 577-591, April 2026.Abstract Objective Sialidosis type I (ST‐1) is an autosomal‐recessive, very rare, progressive lysosomal storage disorder caused by pathogenic variants in NEU1. It is clinically characterized by progressive ataxia, myoclonic seizures (MS), bilateral tonic–clonic seizures (BTCS), and distinctive ophthalmological findings.
Janina Gburek‐Augustat +15 more
wiley +1 more source
Persistent genital arousal symptoms in a young woman with recurring brief psychoses: a clinical dilemma in antipsychotic choice. [PDF]
J Psychiatry NeurosciFortin-Latour É, Stip E.
europepmc +1 more source
Movement Disorders, Volume 41, Issue 4, Page 815-825, April 2026.Abstract Background The first International Parkinson and Movement Disorder Society Evidence‐Based Medicine (MDS‐EBM) review for essential tremor (ET) was published in 2019; since then, the modified Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was adopted by MDS, and new evidence exists.
Deepa Dash +12 more
wiley +1 more source
Obesity, Volume 34, Issue 4, Page 952-960, April 2026.ABSTRACT Objective This study aimed to evaluate the trends in antiobesity medication (AOM) and metabolic and bariatric surgery (MBS) use relative to the 2013 American Medical Association (AMA) declaration of obesity as a chronic disease and semaglutide approval in 2021 in the United States.
Olajide A. Adekunle +7 more
wiley +1 more source